BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 10465276)

  • 1. Regulation of urokinase production by androgens in human prostate cancer cells: effect on tumor growth and metastases in vivo.
    Xing RH; Rabbani SA
    Endocrinology; 1999 Sep; 140(9):4056-64. PubMed ID: 10465276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen regulation of parathyroid hormone-related peptide production in human prostate cancer cells.
    Pizzi H; Gladu J; Carpio L; Miao D; Goltzman D; Rabbani SA
    Endocrinology; 2003 Mar; 144(3):858-67. PubMed ID: 12586762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo.
    Pakneshan P; Xing RH; Rabbani SA
    FASEB J; 2003 Jun; 17(9):1081-8. PubMed ID: 12773490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
    Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer.
    Inoue K; Slaton JW; Eve BY; Kim SJ; Perrotte P; Balbay MD; Yano S; Bar-Eli M; Radinsky R; Pettaway CA; Dinney CP
    Clin Cancer Res; 2000 May; 6(5):2104-19. PubMed ID: 10815938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo.
    Rabbani SA; Gladu J
    Cancer Res; 2002 Apr; 62(8):2390-7. PubMed ID: 11956102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
    Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo.
    Shukeir N; Pakneshan P; Chen G; Szyf M; Rabbani SA
    Cancer Res; 2006 Sep; 66(18):9202-10. PubMed ID: 16982764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA).
    Rabbani SA; Harakidas P; Davidson DJ; Henkin J; Mazar AP
    Int J Cancer; 1995 Dec; 63(6):840-5. PubMed ID: 8847143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
    Xing RH; Mazar A; Henkin J; Rabbani SA
    Cancer Res; 1997 Aug; 57(16):3585-93. PubMed ID: 9270032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
    Siu SW; Lau KW; Tam PC; Shiu SY
    Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: role of epigenetic mechanisms.
    Hagelgans A; Menschikowski M; Fuessel S; Nacke B; Arneth BM; Wirth MP; Siegert G
    Exp Mol Pathol; 2013 Jun; 94(3):458-65. PubMed ID: 23541763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells.
    Gao J; Isaacs JT
    Cancer Res; 1998 Aug; 58(15):3299-306. PubMed ID: 9699659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
    Joseph IB; Nelson JB; Denmeade SR; Isaacs JT
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
    Yoshida E; Verrusio EN; Mihara H; Oh D; Kwaan HC
    Cancer Res; 1994 Jun; 54(12):3300-4. PubMed ID: 8205553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells.
    Miyazaki H; Watabe T; Kitamura T; Miyazono K
    Oncogene; 2004 Dec; 23(58):9326-35. PubMed ID: 15531927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA).
    Hall CL; Tsan R; Mugnai G; Mazar A; Radinsky R; Pettaway CA
    Prostate; 2004 May; 59(2):167-76. PubMed ID: 15042617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.